Vai al contenuto principale

Myeloma Unit

Prof. Mario Boccadoro (Principal Investigator)



The Myeloma Unit, led by Prof. Mario Boccadoro, is a referral center for the research on newly diagnosed and relapsed/refractory multiple myeloma. The Unit is involved in the design, development and coordination of national and international multicenter phase I/II/III clinical trials. As for transplant-ineligible patients, Prof. Boccadoro’s team has had a central role in investigating the efficacy and safety of various drug combinations and in evaluating the role of different sequential approaches. In younger patients, the Unit has been a key element to assess the role of high-dose therapy and stem-cell transplantation in the era of novel agents and combinations. In particular, the Myeloma Unit has been playing a fundamental role in the research on minimal residual disease and in the evaluation of new drugs, such as 2nd generation proteasome inhibitors, immunomodulatory drugs and immunotherapeutic agents. All these activities fostered active collaborations with other national and international research groups.




  • EMN07/IST-CAR-538 (NCT02185820) - A multicenter, open label phase I/II study of carfilzomib, pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma (MM) patients
  • eNAMPT (NCT04137523) - Indagine sul ruolo di eNAMPT nell’acquisizione della transizione epitelio - mesenchimale nel Mieloma Multiplo
  • IMMUNE-UNITO (NCT04135079) - Immune Profiling in Multiple Myeloma
  • Real MM (NCT03829371) - Study comparing two standard treatments in autologous stem cell transplantation ineligible population affected by Multiple Myeloma
  • IG-20541 (NCT03848676) - Genomic and phenotypic determinants of resistance to immunotherapies in Multiple Myeloma
  • UNITO-MM-01/FORTE (NCT02203643) - A multicenter, randomized, open label phase II study of carfilzomib, cyclophosphamide and dexamethasone (CCyd) as pre transplant induction and post transplant consolidation or carfilzomib, lenalidomide and dexamethasone (CRd) as pre transplant induction and post transplant consolidation or continuous treatment with carfilzomib, lenalidomide and dexamethasone (12 cycles) without transplant, all followed by maintenance with lenalidomide (R) versus lenalidomide and carfilzomib (cr) in newly diagnosed Multiple MyelomA (MM) patients elegible for autologous transplant. (FORTE)
  • UNITO-EMN10 (NCT02586038) - A multiarm open label, randomized phase ii study of MLN9708 plus oral dexamethasone or plus oral cyclophosphamide and dexamethasone or plus oral thalidomide and dexamethasone followed by maintenance with MLN9708 in newly diagnosed elderly multiple myeloma patients
  • MMpredict (NCT03409692) - Validation of a Personalised Medicine Tool for Multiple Myeloma That Predicts Treatment Effectiveness in Patients (MMpredict)
  • HARMONY - Healthcare Alliance for Resourceful Medicines Offensive Against Neoplasms in hematology




Ultimo aggiornamento: 08/04/2022 12:34
Non cliccare qui!